Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.

NCT02559921 is registered in ClinicalTrials.gov with Beijing Chaoyang District Centre for Disease Control and Prevention as lead sponsor.

NCT NCT02559921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02559921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.
Lead sponsor
Beijing Chaoyang District Centre for Disease Control and Prevention
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
December 31, 2015
Enrollment
300 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rabies